"Microdosing" GLP-1s has become a marketing category. Programs sell low doses of semaglutide or tirzepatide for longevity, menopause, appetite "maintenance" or fewer side effects. The term has no standard dosing definition, and the cited trials do not establish its promoted benefits. What does exist is useful, though: label doses with clear purposes, early dose-finding trials, pivotal treatment trials and observational prescription records. For the drugs themselves, see our compounded semaglutide guide and our compounded tirzepatide guide.
"Microdosing" has several different meanings
The term can describe staying on an initiation dose, taking less than a labeled dose, or buying a separately marketed wellness plan. Those are different exposures. A product name alone does not establish the amount prescribed, its formulation or whether it matches a studied treatment.
A 2026 brief report for nurse practitioners describes what's driving it: stomach side effects at higher doses, cost, and the end of shortage-era compounding. It also lists the risks clinicians see, including dosing errors, pen manipulation, compounded vials and shared medication [8]. This is clinical commentary, not a measured explanation of how often people microdose or why the trend developed.
The cited trial results do not establish microdosing benefits
It would be incorrect to say that lower doses have never been randomized. A 12-week phase 2 semaglutide study randomized 415 adults with type 2 diabetes to several doses, placebo or open-label liraglutide. Some semaglutide doses were below the current Wegovy initiation dose. The primary outcome was blood-sugar control, and gastrointestinal adverse events increased with dose. This was not a trial of a commercial compounded longevity plan [10].
A 26-week phase 2 tirzepatide trial randomized 318 adults with type 2 diabetes and also included a dose below the current Zepbound initiation dose. In its lowest-dose arm, HbA1c changed by −1.06 percentage points versus −0.06 with placebo; gastrointestinal events occurred in 23.1% versus 9.8%. These results prevent a blanket claim of no low-dose trials. They do not establish safety or benefit for another preparation, schedule, population or wellness goal [11].
The newer records study identified 814 semaglutide patients and 1,016 tirzepatide patients with at least three distinct starting-dose prescription dates spanning six months. Average recorded weight changes at 12 months were −2.2% and −5.5%, respectively. Prescription records do not confirm dispensing, administration, adherence or intentional microdosing. Treatment outside the system and differences in who had follow-up measurements could affect the results [9].
These are observational associations, not a randomized comparison between drugs or doses. Residual confounding, sparse prescription records and selection of patients with available measurements limit causal interpretation. The authors work for nference, which collaborates with biopharmaceutical companies, but disclose no industry funding, support or role in this study. The records cannot establish that a marketed microdose plan caused the observed changes [9].
Initiation and maintenance depend on the drug and indication
Both brand labels begin low on purpose. Wegovy's injection starts at 0.25 mg once weekly for weeks 1 to 4, then steps through 0.5 mg, 1 mg and 1.7 mg before a maintenance dose from week 17 [1]. Zepbound starts at 2.5 mg once weekly for four weeks and limits that strength to treatment initiation, excluding it from approved maintenance [2].
Escalation helps manage gastrointestinal tolerability, but the labels have different maintenance instructions. Current Wegovy injection options include selected adults who need additional weight reduction after tolerating the usual maintenance dose. Zepbound weight-management maintenance doses differ from its sleep-apnea maintenance options. These details cannot be transferred to another formulation or indication [1] [2].
Semaglutide evidence needs a specific treatment context
Wegovy injection uses 0.25 mg as an initiation dose. The trial that earned Wegovy its weight-loss approval tested 2.4 mg weekly. In STEP 1, 1,961 adults with overweight or obesity lost an average of 14.9% of body weight at 68 weeks, against 2.4% on placebo [4].
The prescribed device and formulation matter. Do not change a pen, share medication or infer a liquid measurement from a milligram amount. Different vial concentrations can require different measurements, which the prescriber and dispensing pharmacist must explain. The Wegovy tablet has separate administration requirements and evidence, covered in the oral semaglutide guide [3].
Microdosing tirzepatide follows the same pattern
Zepbound's weight-management maintenance doses are 5, 10 and 15 mg. In SURMOUNT-1, even the lowest of those, 5 mg weekly, produced an average 15.0% weight loss at 72 weeks [5]. Early dose-finding trials did include a lower dose, but do not validate a separate commercial wellness regimen. The guide to microdosing tirzepatide covers that drug in more depth.
The longevity pitch borrows a heart trial that tested full doses
Longevity marketing often cites SELECT. In that trial, 17,604 adults with heart disease and overweight or obesity, but without diabetes, took semaglutide 2.4 mg or placebo. Major cardiovascular events fell from 8.0% to 6.5% of patients, a hazard ratio of 0.80 (95% confidence interval 0.72–0.90) [7]. It's a real benefit. But SELECT tested the full 2.4 mg dose, in people with existing heart disease, and it measured heart attacks, strokes and cardiovascular death, not aging.
The registry for NCT07293325 lists a recruiting study of adults with obesity, with a 24-week DNA-methylation measure as its primary outcome. Its last posted update is from December 2025, and the registry has no posted results; that is not independent confirmation that enrollment remains open. Its planned treatment schedules are not evidence for commercial microdosing. A change in an aging biomarker would also require validation before being treated as longer life or improved healthspan [12].
If longevity is your goal, the evidence questions are similar for the other off-label options. See metformin for longevity and our rapamycin guide.
Dose accuracy, product quality and drug risks still matter
A smaller prescribed amount does not establish that a compounded preparation is safer. Measurement still requires instructions for the exact concentration and device. FDA has received multiple reports of adverse events, some requiring hospitalization, that may be related to dosing errors with compounded injectable semaglutide, from patients measuring wrong amounts and sometimes from clinicians miscalculating them [3].
- Vial strength varies between pharmacies, so the same milligram dose is a different volume from one vial to another. FDA urges patients to ask their prescriber or compounder how to measure their dose.
- Opened-vial disposal matters. FDA recommends discarding a multi-dose vial within 28 days after first puncture. An earlier beyond-use date, expiration or storage problem can require earlier disposal.
- Salt forms such as semaglutide sodium or acetate are different active ingredients, and FDA knows of no lawful basis for compounding them.
- Warm deliveries shouldn't be used, according to FDA, because heat can affect quality.
Those points all come from FDA's page on unapproved GLP-1 drugs [3]. A shipment containing several unopened vials is different from keeping one punctured vial for months. Ask the pharmacist to reconcile the labeled storage conditions, beyond-use date and first-puncture disposal instructions. Compounded drugs do not receive FDA premarket review for safety, effectiveness or quality.
The labels already allow a slower pace when a dose isn't tolerated
There's a label-backed version of "going slow." Wegovy's label says that if a patient doesn't tolerate a dose during the step-up, prescribers can consider delaying the next increase by four weeks [1]. Zepbound directs maintenance selection according to response and tolerability, but explicitly excludes its initiation dose from approved maintenance. That is not permission to treat every lower dose or schedule as label-supported [2].
The medical assessment also includes contraindications and serious risks, not just stomach symptoms. The labels contraindicate use with a personal or family history of medullary thyroid carcinoma, MEN2 or serious hypersensitivity to the relevant drug. A lower amount does not remove those contraindications or prove protection from other adverse effects [1] [2].
What microdose programs charge
Request the amount due today, the recurring charge, actual renewal interval, medication quantity, separate fees and cancellation deadline. A 28-day supply does not by itself prove a 28-day charge interval. Prepaying several months may lower an advertised equivalent while increasing the money committed before treatment response is known. Our billing checklist and coverage-cost worksheet help organize that written quote.
Ask the treating professional what evidence supports the specific preparation and treatment goal, how response and adverse effects will be assessed, and what would prompt a change or discontinuation. A cheaper plan is not a clinical reason to change the prescribed amount. The absence of a matching trial also does not prove that an individual will experience no effect; it means the claimed benefit and risk remain uncertain.